Guided Therapeutics (GTHP) Long-Term Investments (2025)
Guided Therapeutics (GTHP) reported Long-Term Investments of $472502.0 for Q4 2025.
Guided Therapeutics (GTHP) Long-Term Investments (2025) Analysis & Trends
Guided Therapeutics (GTHP) has 1 years of Long-Term Investments data on file, last reported at $472502.0 in Q4 2025.
- For the quarter ending Q4 2025, Long-Term Investments changed N/A year-over-year to $472502.0; the trailing twelve-month figure through Dec 2025 stood at $472502.0 (changed N/A YoY), and the FY2025 full-year result was $472502.0, changed N/A from the prior year.
- Long-Term Investments steadied at $472502.0 in Q4 2025.
- In the past five years, Long-Term Investments ranged from a high of $472502.0 in Q4 2025 to a low of $472502.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.09 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 285.60 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 166.25 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 121.00 Mn |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | 472,502.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 472,502.00 |